10:43 AM EDT, 06/18/2024 (MT Newswires) -- Ionis Pharmaceuticals ( IONS ) said Tuesday it signed a license agreement with Otsuka Pharmaceutical giving Otsuka exclusive rights for donidalorsen, an investigational treatment for hereditary angioedema, across the Asia-Pacific region.

Ionis said it will receive a $20 million upfront payment and milestone payments based on the achievement of regulatory and sales targets, as well as potential tiered royalties.

The company will retain primary responsibility for the development of donidalorsen, while Otsuka will be in charge of territory-specific development, regulatory filings and commercialization in the Asia-Pacific region and Europe, Ionis said.

Ionis said it intends to file a new drug application with the US Food and Drug Administration in 2024. It will independently launch donidalorsen in the US, if approved.

Hereditary angioedema is a rare and potentially life-threatening genetic condition that involves recurrent attacks of severe swelling in various body parts.

Price: 40.63, Change: -0.13, Percent Change: -0.32